Moderna Delivers First Canadian-Made mRNA Vaccines

Moderna has achieved a significant milestone by delivering the first mRNA vaccines fully manufactured in Canada to provinces and territories. This development is a key step in boosting Canada's domestic vaccine production and enhancing national health security. The Spikevax® COVID-19 vaccine, targeting the SARS-CoV-2 LP.8.1 variant, is produced in Laval, Quebec and filled in Cambridge, Ontario. This vaccine was approved by Health Canada on August 21, 2025.

Eligibility for the vaccination program is determined by each province and territory, with free access for eligible individuals. Moderna's efforts are supported by partnerships with private insurers to ensure broader access. This initiative highlights Canada's manufacturing capability and collaboration between sectors, aiming to safeguard public health and encourage economic growth.